{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:59:08Z","timestamp":1792511948290,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Confined placental mosaicism can cause false-positive prenatal cell-free DNA (cfDNA) screening results, thereby reducing the positive predictive value (PPV) of the test. We sought to investigate how PPVs for the common fetal trisomies can be refined based on the presence or absence of chromosomal mosaicism in cfDNA sequencing data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study cohort included singleton pregnancies tested between March 2019 and December 2021. Outcome data were requested for high-risk results. Mosaic ratio (MR) generated by VeriSeq NIPT Solution v2 was used to classify high-risk cfDNA results as mosaic trisomy (MR &amp;lt; 0.7) or non-mosaic trisomy (MR \u2265 0.7) and the PPVs calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The cohort consisted of 821 high-risk results from 76 329 tests (1.08%). Prior to applying MR, PPVs for T21, T18 and T13 were 93.3% [95% CI 90.2\u201395.5], 81% [95% CI 73.1\u201387.0], and 55.3% [95% CI 44.7\u201365.4], respectively. After applying MR, PPVs for non-mosaic trisomy results were significantly higher (P &amp;lt; 0.001) than the PPVs for mosaic trisomy results; T21: 99.3% and 50%, T18: 97.6% and 22.7%, T13: 93.9% and 0%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Mosaic ratio can be used to calculate more specific PPVs for the common trisomies. There is currently limited guidance on the application of VeriSeq v2 MR. Our approach provides a framework for laboratories to consider using MRs to refine PPV estimates for the common trisomies. High-risk cfDNA screening results are distressing for tested individuals. A refined PPV incorporating the presence or absence of mosaicism provides patients with more accurate information on the likely outcome of the diagnostic testing result, helping guide genetic counseling, choice of prenatal procedure, and overall pregnancy management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvaf076","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:18:57Z","timestamp":1753715937000},"page":"1036-1046","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of Placental Chromosomal Mosaicism during Prenatal Cell-Free DNA Screening Refines Positive Predictive Values for Fetal Trisomy"],"prefix":"10.1093","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4338-3374","authenticated-orcid":false,"given":"Nicola J","family":"Flowers","sequence":"first","affiliation":[{"name":"Victorian Clinical Genetics Services, Murdoch Children\u2019s Research Institute , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J","family":"Love","sequence":"additional","affiliation":[{"name":"Victorian Clinical Genetics Services, Murdoch Children\u2019s Research Institute , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina L","family":"Scarff","sequence":"additional","affiliation":[{"name":"Victorian Clinical Genetics Services, Murdoch Children\u2019s Research Institute , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Giouzeppos","sequence":"additional","affiliation":[{"name":"Victorian Clinical Genetics Services, Murdoch Children\u2019s Research Institute , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison D","family":"Archibald","sequence":"additional","affiliation":[{"name":"Victorian Clinical Genetics Services, Murdoch Children\u2019s Research Institute , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Paediatrics, University of Melbourne , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B","family":"Delatycki","sequence":"additional","affiliation":[{"name":"Victorian Clinical Genetics Services, Murdoch Children\u2019s Research Institute , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Paediatrics, University of Melbourne , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8363-2879","authenticated-orcid":false,"given":"Mark D","family":"Pertile","sequence":"additional","affiliation":[{"name":"Victorian Clinical Genetics Services, Murdoch Children\u2019s Research Institute , Melbourne, Victoria ,","place":["Australia"]},{"name":"Department of Paediatrics, University of Melbourne , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2025100219513575200_hvaf076-B1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/uog.17484","article-title":"Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis","volume":"50","author":"Gil","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025100219513575200_hvaf076-B2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/medethics-2018-105167","article-title":"\u2018Is it better not to know certain things?\u2019: views of women who have undergone non-invasive prenatal testing on its possible future applications","volume":"45","author":"Bowman-Smart","year":"2019","journal-title":"J Med Ethics"},{"key":"2025100219513575200_hvaf076-B3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s10897-018-0250-8","article-title":"Talking points: women\u2019s information needs for informed decision-making about noninvasive prenatal testing for down syndrome","volume":"27","author":"Dane","year":"2018","journal-title":"J Genet Couns"},{"key":"2025100219513575200_hvaf076-B4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.gim.2022.03.019","article-title":"Systematic evidence-based review: the application of noninvasive prenatal screening using cell-free DNA in general-risk pregnancies","volume":"24","author":"Rose","year":"2022","journal-title":"Genet Med"},{"key":"2025100219513575200_hvaf076-B5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/14737159.2016.1152890","article-title":"Cytogenetic confirmation of a positive NIPT result: evidence-based choice between chorionic villus sampling and amniocentesis depending on chromosome aberration","volume":"16","author":"Van Opstal","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"2025100219513575200_hvaf076-B6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/uog.15975","article-title":"Implications of fetoplacental mosaicism on cell-free DNA testing: a review of a common biological phenomenon","volume":"48","author":"Grati","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025100219513575200_hvaf076-B7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cge.12598","article-title":"Clinical implementation of NIPT\u2014technical and biological challenges","volume":"89","author":"Brady","year":"2016","journal-title":"Clin Genet"},{"key":"2025100219513575200_hvaf076-B8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/humrep\/deh117","article-title":"Circulating cell-free fetal DNA in maternal serum appears to originate from cyto- and syncytio-trophoblastic cells. Case report","volume":"19","author":"Flori","year":"2004","journal-title":"Hum Reprod"},{"key":"2025100219513575200_hvaf076-B9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pd.1970120503","article-title":"Cytogenetic results from the U.S. collaborative study on CVS","volume":"12","author":"Ledbetter","year":"1992","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/pd.1970090807","article-title":"The European collaborative study on mosaicism in chorionic villus sampling: data from 1986 to 1987","volume":"9","author":"Vejerslev","year":"1989","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/pd.1970140505","article-title":"Confined placental mosaicism, IUGR, and adverse pregnancy outcome: a controlled retrospective U.K. collaborative survey","volume":"14","author":"Wolstenholme","year":"1994","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/pd.5863","article-title":"Impact of mosaicism ratio on positive predictive value of cfDNA screening","volume":"41","author":"Rafalko","year":"2021","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B13","doi-asserted-by":"crossref","first-page":"eaan1240","DOI":"10.1126\/scitranslmed.aan1240","article-title":"Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of feto-placental disease","volume":"9","author":"Pertile","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025100219513575200_hvaf076-B14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/pd.5223","article-title":"Predicting fetoplacental chromosomal mosaicism during non-invasive prenatal testing","volume":"38","author":"Brison","year":"2018","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/gim.2017.56","article-title":"Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases","volume":"19","author":"Ehrich","year":"2017","journal-title":"Genet Med"},{"key":"2025100219513575200_hvaf076-B16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/clinchem\/hvab067","article-title":"Performance of a paired-end sequencing-based noninvasive prenatal screening test in the detection of genome-wide fetal chromosomal anomalies","volume":"67","author":"Pertile","year":"2021","journal-title":"Clin Chem"},{"key":"2025100219513575200_hvaf076-B17","author":"Illumina"},{"key":"2025100219513575200_hvaf076-B18","author":"VCGS"},{"key":"2025100219513575200_hvaf076-B19","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/pd.6680","article-title":"Confined placental mosaicism detected with non-invasive prenatal testing: is there an association between mosaic ratio and pregnancy outcome?","volume":"44","author":"Eggenhuizen","year":"2024","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/pd.4656","article-title":"Interpreting mosaicism in chorionic villi: results of a monocentric series of 1001 mosaics in chorionic villi with follow-up amniocentesis","volume":"35","author":"Malvestiti","year":"2015","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/pd.4024","article-title":"Fetal aneuploidy screening by maternal plasma DNA sequencing: \u2018false positive\u2019 due to confined placental mosaicism","volume":"33","author":"Choi","year":"2013","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/gim.2014.3","article-title":"Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results","volume":"16","author":"Grati","year":"2014","journal-title":"Genet Med"},{"key":"2025100219513575200_hvaf076-B23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/uog.13334","article-title":"Abnormal non-invasive prenatal test results concordant with karyotype of cytotrophoblast but not reflecting abnormal fetal karyotype","volume":"44","author":"Srebniak","year":"2014","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025100219513575200_hvaf076-B24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/pd.4659","article-title":"The type of feto-placental aneuploidy detected by cfDNA testing may influence the choice of confirmatory diagnostic procedure","volume":"35","author":"Grati","year":"2015","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B25","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/pd.5766","article-title":"Noninvasive prenatal testing as compared to chorionic villus sampling is more sensitive for the detection of confined placental mosaicism involving the cytotrophoblast","volume":"40","author":"Van Opstal","year":"2020","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/GCO.0000000000000610","article-title":"Predicting fetoplacental mosaicism during cfDNA-based NIPT","volume":"32","author":"Neofytou","year":"2020","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2025100219513575200_hvaf076-B27","doi-asserted-by":"crossref","first-page":"e0248467","DOI":"10.1371\/journal.pone.0248467","article-title":"Application of mosaicism ratio to multifetal gestations","volume":"16","author":"Rafalko","year":"2021","journal-title":"PLoS One"},{"key":"2025100219513575200_hvaf076-B28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ccr3.1424","article-title":"Discordant NIPT result in a viable trisomy-21 pregnancy due to prolonged contribution to cfDNA by a demised trisomy-14 cotwin","volume":"6","author":"Hochstenbach","year":"2018","journal-title":"Clin Case Rep"},{"key":"2025100219513575200_hvaf076-B29","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/pd.6357","article-title":"Position statement from the International Society for Prenatal Diagnosis (ISPD) on the use of non-invasive prenatal testing (NIPT) for the detection of fetal chromosomal conditions in singleton pregnancies","volume":"43","author":"Hui","year":"2023","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B30","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.gim.2022.11.004","article-title":"Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Dungan","year":"2022","journal-title":"Genet Med"},{"key":"2025100219513575200_hvaf076-B31","author":"Royal Australia and New Zealand College of Obstetricians and Gynaecologists (RANZCOG)"},{"key":"2025100219513575200_hvaf076-B32","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/pd.6021","article-title":"Diagnostic testing after positive results on cell free DNA screening: CVS or Amnio?","volume":"41","author":"Mardy","year":"2021","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/uog.26272","article-title":"Late first-trimester ultrasound findings can alter management after high-risk NIPT result","volume":"62","author":"Scott","year":"2023","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025100219513575200_hvaf076-B34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pd.6307","article-title":"Performance of a cell-free DNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low-risk cell-free DNA screening","volume":"43","author":"Scarff","year":"2023","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/(SICI)1097-0223(200002)20:2<103::AID-PD761>3.0.CO;2-K","article-title":"Common trisomy mosaicism diagnosed in amniocytes involving chromosomes 13, 18, 20 and 21: karyotype-phenotype correlations","volume":"20","author":"Wallerstein","year":"2000","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B36","author":"Australian Bureau of Statistics"},{"key":"2025100219513575200_hvaf076-B37","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ajhg.2019.10.005","article-title":"TRIDENT-2: national implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in The Netherlands","volume":"105","author":"van der Meij","year":"2019","journal-title":"Am J Hum Genet"},{"key":"2025100219513575200_hvaf076-B38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41436-021-01101-4","article-title":"Outcome of publicly funded nationwide first-tier noninvasive prenatal screening","volume":"23","author":"Van Den Bogaert","year":"2021","journal-title":"Genet Med"},{"key":"2025100219513575200_hvaf076-B39","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/pd.4625","article-title":"Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing","volume":"35","author":"Kinnings","year":"2015","journal-title":"Prenat Diagn"},{"key":"2025100219513575200_hvaf076-B40","author":"European Molecular Genetics Quality Network (EMQN)"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/71\/10\/1036\/63865646\/hvaf076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/71\/10\/1036\/63865646\/hvaf076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:51:47Z","timestamp":1759449107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/71\/10\/1036\/8215439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvaf076","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,7,28]]}}}